Cargando…
The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States
BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general populati...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847750/ https://www.ncbi.nlm.nih.gov/pubmed/34991361 http://dx.doi.org/10.1177/17407745211069153 |
_version_ | 1784652112646373376 |
---|---|
author | Umaefulam, Valerie Kleissen, Tessa Barnabe, Cheryl |
author_facet | Umaefulam, Valerie Kleissen, Tessa Barnabe, Cheryl |
author_sort | Umaefulam, Valerie |
collection | PubMed |
description | BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general population to Indigenous peoples. Indigenous population–specific clinical studies, and inclusion of Indigenous peoples in general population clinical trials, are perceived to be rare. Our study (1) identified and characterized Indigenous population–specific chronic disease trials and (2) identified the representation of Indigenous peoples in general population chronic disease trials conducted in Australia, Canada, New Zealand, and the United States. METHODS: For Objective 1, publicly available clinical trial registries were searched from May 2010 to May 2020 using Indigenous population–specific terms and included for data extraction if in pre-specified chronic disease. For identified trials, we extracted Indigenous population group identity and characteristics, type of intervention, and funding type. For Objective 2, a random selection of 10% of registered clinical trials was performed and the proportion of Indigenous population participants enrolled extracted. RESULTS: In total, 170 Indigenous population–specific chronic disease trials were identified. The clinical trials were predominantly behavioral interventions (n = 95). Among general population studies, 830 studies were randomly selected. When race was reported in studies (n = 526), Indigenous individuals were enrolled in 172 studies and constituted 5.6% of the total population enrolled in those studies. CONCLUSION: Clinical trials addressing chronic disease conditions in Indigenous populations are limited. It is crucial to ensure adequate representation of Indigenous peoples in clinical trials to ensure trial data are applicable to their clinical care. |
format | Online Article Text |
id | pubmed-8847750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88477502022-02-17 The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States Umaefulam, Valerie Kleissen, Tessa Barnabe, Cheryl Clin Trials Articles BACKGROUND: Indigenous peoples are overrepresented with chronic health conditions and experience suboptimal outcomes compared with non-Indigenous peoples. Genetic variations influence therapeutic responses, thus there are potential risks and harm when extrapolating evidence from the general population to Indigenous peoples. Indigenous population–specific clinical studies, and inclusion of Indigenous peoples in general population clinical trials, are perceived to be rare. Our study (1) identified and characterized Indigenous population–specific chronic disease trials and (2) identified the representation of Indigenous peoples in general population chronic disease trials conducted in Australia, Canada, New Zealand, and the United States. METHODS: For Objective 1, publicly available clinical trial registries were searched from May 2010 to May 2020 using Indigenous population–specific terms and included for data extraction if in pre-specified chronic disease. For identified trials, we extracted Indigenous population group identity and characteristics, type of intervention, and funding type. For Objective 2, a random selection of 10% of registered clinical trials was performed and the proportion of Indigenous population participants enrolled extracted. RESULTS: In total, 170 Indigenous population–specific chronic disease trials were identified. The clinical trials were predominantly behavioral interventions (n = 95). Among general population studies, 830 studies were randomly selected. When race was reported in studies (n = 526), Indigenous individuals were enrolled in 172 studies and constituted 5.6% of the total population enrolled in those studies. CONCLUSION: Clinical trials addressing chronic disease conditions in Indigenous populations are limited. It is crucial to ensure adequate representation of Indigenous peoples in clinical trials to ensure trial data are applicable to their clinical care. SAGE Publications 2022-01-06 2022-02 /pmc/articles/PMC8847750/ /pubmed/34991361 http://dx.doi.org/10.1177/17407745211069153 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 Lficense (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Articles Umaefulam, Valerie Kleissen, Tessa Barnabe, Cheryl The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title | The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title_full | The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title_fullStr | The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title_full_unstemmed | The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title_short | The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States |
title_sort | representation of indigenous peoples in chronic disease clinical trials in australia, canada, new zealand, and the united states |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847750/ https://www.ncbi.nlm.nih.gov/pubmed/34991361 http://dx.doi.org/10.1177/17407745211069153 |
work_keys_str_mv | AT umaefulamvalerie therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates AT kleissentessa therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates AT barnabecheryl therepresentationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates AT umaefulamvalerie representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates AT kleissentessa representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates AT barnabecheryl representationofindigenouspeoplesinchronicdiseaseclinicaltrialsinaustraliacanadanewzealandandtheunitedstates |